A peptide that binds specifically to the β-Amyloid of alzheimer's disease: Selection and assessment of anti-β-Amyloid neurotoxic effects

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Wang, Fang ^a   Zhou, Xian Ling ^a   Yang, Qi Gang ^a   Xu, Wen Hua ^a   Wang, Fei ^a   Chen, Yong Ping ^b   Chen, Gui Hai ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-10]; AMYLOID BETA PROTEIN[1-42]; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CELL STRAIN; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SCREENING; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN AGGREGATION; RAT; AMYLOID PLAQUE; ANIMAL; METABOLISM; PATHOLOGY; PEPTIDE LIBRARY; SPRAGUE DAWLEY RAT; TOXICITY AND INTOXICATION;

RATTUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; MALE; MAZE LEARNING; NEUROTOXICITY SYNDROMES; PC12 CELLS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PLAQUE, AMYLOID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80755152357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027649     Document Type: Article

References (66)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
2. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
3. Selkoe DJ, (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271: 18295-18298.
4. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, et al. (2000) Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39: 6288-6295.
5. Crews L, Masliah E, (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19: R12-20.
6. Findeis MA, (2007) The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116: 266-286.
7. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
8. Glabe CG, (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639-29643.
9. Crouch PJ, Harding SM, White AR, Camakaris J, Bush AI, et al. (2008) Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 40: 181-198.
10. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG, (2009) Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13: 412-421.
11. Qahwash I, Weiland KL, Lu Y, Sarver RW, Kletzien RF, et al. (2003) Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. J Biol Chem 278: 23187-23195.
12. Orner BP, Liu L, Murphy RM, Kiessling LL, (2006) Phage display affords peptides that modulate beta-amyloid aggregation. J Am Chem Soc 128: 11882-11889.
13. Solomon B, (2007) Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease. Drugs Today (Barc) 43: 333-342.
14. Nelson TJ, Alkon DL, (2007) Protection against beta-amyloid-induced apoptosis by peptides interacting with beta-amyloid. J Biol Chem 282: 31238-31249.
15. Liu R, McAllister C, Lyubchenko Y, Sierks MR, (2004) Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J Neurosci Res 75: 162-171.
16. Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, et al. (2004) Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol Chem 279: 52781-52788.
17. Cummings JL, Doody R, Clark C, (2007) Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69: 1622-1634.
18. Schenk D, (2004) Hopes remain for an Alzheimer's vaccine. Nature 431: 398.
19. Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D'Introno A, et al. (2010) Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 7: 40-55.
20. Thomas T, Nadackal TG, Thomas K, (2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12: 3263-3267.
21. Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer-Attali R, et al. (2011) Orally administrated cinnamon extract reduces beta-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One 6: e16564.
22. Ladner RC, Sato AK, Gorzelany J, de Souza M, (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9: 525-529.
23. Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, et al. (2008) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry 47: 1984-1992.
24. Matharu B, El-Agnaf O, Razvi A, Austen BM, (2010) Development of retro-inverso peptides as anti-aggregation drugs for beta-amyloid in Alzheimer's disease. Peptides 31: 1866-1872.
25. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, et al. (2010) Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 49: 3261-3272.
26. Hughes E, Burke RM, Doig AJ, (2000) Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem 275: 25109-25115.
27. Sciarretta KL, Boire A, Gordon DJ, Meredith SC, (2006) Spatial separation of beta-sheet domains of beta-amyloid: disruption of each beta-sheet by N-methyl amino acids. Biochemistry 45: 9485-9495.
28. Gordon DJ, Tappe R, Meredith SC, (2002) Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. J Pept Res 60: 37-55.
29. Cruz M, Tusell JM, Grillo-Bosch D, Albericio F, Serratosa J, et al. (2004) Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. J Pept Res 63: 324-328.
30. Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ, (2006) N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 45: 9906-9918.
31. Findeis MA, (2002) Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2: 417-423.
32. Amijee H, Madine J, Middleton DA, Doig AJ, (2009) Inhibitors of protein aggregation and toxicity. Biochem Soc Trans 37: 692-696.
33. Hatip FF, Hatip-Al-Khatib I, Matsunaga Y, Suenaga M, Sen N, (2010) Effects of 8-residue beta sheet breaker peptides on aged Abeta40-induced memory impairment and Abeta40 expression in rat brain and serum following intraamygdaloid injection. Curr Alzheimer Res 7: 602-614.
34. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, et al. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4: 822-826.
35. Chacon MA, Barria MI, Soto C, Inestrosa NC, (2004) Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry 9: 953-961.
36. Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, et al. (1997) Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 272: 12601-12605.
37. Granic I, Masman MF, Kees Mulder C, Nijholt IM, Naude PJ, et al. (2010) LPYFDa neutralizes amyloid-beta-induced memory impairment and toxicity. J Alzheimers Dis 19: 991-1005.
38. Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, et al. (2003) Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display. Chembiochem 4: 748-753.
39. Wiesehan K, Stohr J, Nagel-Steger L, van Groen T, Riesner D, et al. (2008) Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel 21: 241-246.
40. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, et al. (2008) Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem 3: 1848-1852.
41. Zwick MB, Shen J, Scott JK, (1998) Phage-displayed peptide libraries. Curr Opin Biotechnol 9: 427-436.
42. Molek P, Strukelj B, Bratkovic T, (2011) Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 16: 857-887.
43. Kang CK, Jayasinha V, Martin PT, (2003) Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display. Neurobiol Dis 14: 146-156.
44. Larbanoix L, Burtea C, Laurent S, Van Leuven F, Toubeau G, et al. (2010) Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging 31: 1679-1689.
45. Sambrook J, Gething MJ, (1989) Protein structure. Chaperones, paperones. Nature 342: 224-225.
46. Wang R, Zhang HY, Tang XC, (2001) Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 421: 149-156.
47. Chen GH, Wang YJ, Qin S, Yang QG, Zhou JN, et al. (2007) Age-related spatial cognitive impairment is correlated with increase of synaptotagmin 1 in dorsal hippocampus in SAMP8 mice. Neurobiol Aging 28: 611-618.
48. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, et al. (2010) Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. Embo J 29: 3408-3420.
49. Aguzzi A, O'Connor T, (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9: 237-248.
50. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, et al. (1992) Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A 89: 5462-5466.
51. Tanzi RE, Moir RD, Wagner SL, (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43: 605-608.
52. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, et al. (2009) Beta-amyloid monomers are neuroprotective. J Neurosci 29: 10582-10587.
53. Majd S, Zarifkar A, Rastegar K, Takhshid MA, (2008) Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Res 1218: 224-229.
54. Abdul HM, Calabrese V, Calvani M, Butterfield DA, (2006) Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 84: 398-408.
55. Martin D, Salinas M, Lopez-Valdaliso R, Serrano E, Recuero M, et al. (2001) Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 78: 1000-1008.
56. Jellinger KA, (2006) Challenges in neuronal apoptosis. Curr Alzheimer Res 3: 377-391.
57. Harper JD, Lansbury PT Jr, (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407.
58. Tan J, Town T, Placzek A, Kundtz A, Yu H, et al. (1999) Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer's beta-amyloid1-40 peptide in PC12 cells. Neurosci Lett 272: 5-8.
59. Baldi E, Bucherelli C, (2005) The inverted "u-shaped" dose-effect relationships in learning and memory: modulation of arousal and consolidation. Nonlinearity Biol Toxicol Med 3: 9-21.
60. Calabrese EJ, (2008) Hormesis and medicine. Br J Clin Pharmacol 66: 594-617.
61. Yamada M, Chiba T, Sasabe J, Nawa M, Tajima H, et al. (2005) Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 164: 139-146.
62. Olariu A, Yamada K, Mamiya T, Hefco V, Nabeshima T, (2002) Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C. Brain Res 957: 278-286.
63. Shin EJ, Nabeshima T, Lee PH, Kim WK, Ko KH, et al. (2004) Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice. Behav Brain Res 151: 267-276.
64. Youssef I, Florent-Bechard S, Malaplate-Armand C, Koziel V, Bihain B, et al. (2008) N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 29: 1319-1333.
65. Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, et al. (2010) Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226: 274-284.
66. Iijima-Ando K, Hearn SA, Shenton C, Gatt A, Zhao L, et al. (2009) Mitochondrial mislocalization underlies Abeta42-induced neuronal dysfunction in a Drosophila model of Alzheimer's disease. PLoS One 4: e8310.